We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Markers Found for Early Detection of Type 1 Diabetes

By LabMedica International staff writers
Posted on 20 Oct 2009
German researchers have identified new markers that enable an early diagnosis and prognosis of type 1 diabetes.

German scientist investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. More...
The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome. These high-risk individuals require especially careful monitoring.

The research was performed under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München (Germany) and Technische Universität München (Germany).

Worldwide, the number of children who develop type 1 diabetes is increasing. In Germany, approximately 11,000 children are affected. On average, they are eight and a half years old when they are diagnosed with the disease. However, already at this age many children show severe metabolic decompensation. Successful prevention strategies and detailed screening can prevent this.

Prof. Dr. Anette Ziegler and Dr. Peter Achenbach, from Helmholtz Zentrum München and Technische Universität München in cooperation with Prof. Dr. Ezio Bonifacio of Technische Universität Dresden, have developed a new approach to improve and extend risk screening. "Acute severe complications such as diabetic coma at disease onset can thus be avoided in the majority of the children,” Dr. Peter Achenbach explained. The scientists evaluated the data of 1,633 children who had at least one type 1 diabetic parent. These children's risk for diabetes was elevated in comparison with children who had no family history of diabetes.

Genetic factors play a considerable role in the development of type 1 diabetes. The scientists were able to show that specific variants of the zinc transporter gene SLC30A8 influence the risk for diabetes. The body needs this gene in order to produce ZnT8. This protein influences the zinc transport into the beta cells and plays a crucial role in their maturation and thus also in insulin secretion.

Beta cells of the islets of Langerhans in the pancreas secrete the critically important insulin. Already before the onset of type 1 diabetes the body's own immune system destroys the beta cells. If this destruction exceeds a certain threshold, the disease becomes evident: The insulin deficiency leads to various metabolic disturbances, including elevated blood glucose levels.

"Autoantibodies to ZnT8 in combination with a specific variant of the zinc transporter gene were associated with an elevated diabetes risk,” said Dr. Peter Achenbach, from the Institute for Diabetes Research at Helmholtz Zentrum München. "Eighty-one percent of these children with ZnT8 antibodies developed diabetes mellitus.” An increased diabetes risk has long been associated with the islet autoantibodies. These include the autoantibodies to insulin (IAA), islet cell antibodies to the enzyme glutamate decarboxylase (GADA) and to tyrosine phosphatases (IA-2A and IA-2ß).

"Autoantibodies to ZnT8 are an additional important marker for the progression of diabetes--especially in children who are already developing islet autoantibodies,” said Dr. Thomas Illig, from the Institute of Epidemiology at Helmholtz Zentrum München. A differentiated analysis of all autoantibodies allows the prognosis of how fast the disease will become manifest. According to Dr. Illig, the rule of thumb is: The larger the number of different kinds of autoantibodies, the higher the risk for diabetes, and the younger the child with autoantibodies, the earlier disease onset will be.

The study was published in the September 2009 issue of the journal Diabetolgia
Related Links:
Helmholtz Zentrum München
Technische Universität München





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.